The world can’t stop talking about biopharma’s scientific achievements, but the discussion often avoids the industry’s biggest potential buzzkill: a shortage of properly trained workers to manufacture these new drugs.There’s no denying that biopharma drugs will play a vital role in the future of medicine. Biologics make up about 40 percent of the over 16,000 drugs in the global pharma pipeline. These biologic hopefuls include drugs in new therapeutic areas, such as cell and gene therapy, that are igniting the industry on fire with their potential to treat the previously untreatable. The U.S. Food and Drug Administration estimated that by 2020, they will be…Full Story
Take our ultra quick survey for a chance to be quoted in our December issue.